Table 2.
Group | Treatment | Dosage (μg) | No of mice | Immunization days | Bleeding days | GMT Serum antibody (range)
|
|||
---|---|---|---|---|---|---|---|---|---|
Against 16 VLP
|
Against 18 VLP
|
||||||||
35th day | 190th day | 35th day | 190th day | ||||||
1 | Bivalent (HPV16 and 18 VLP) vaccine | HPV16 VLP – 2 μg and HPV18 VLP – 1 μg | 7 | 0, 14 and 28 | 0, 14, 28, 35 and 190 | 5796 (800–25,600) | 317 (100–800) | 2625 (1600–25,600) | 400 (100–1600) |
2 | Placebo | Aluminium Hydroxide | 7 | 0, 14 and 28 | 0, 14, 28, 35 and 190 | 0 | 0 | 0 | 0 |